Interleukin-2, T-cell growth factor (TCGF), Interleukin-2, Lymphokine, IL-2.
Please prevent freeze-thaw cycles.
Amino acid sequence
Safety Data Sheet
Title: Interleukin-2 Human Recombinant, Yeast: A Promising Biopharmaceutical for Immunotherapy
Interleukin-2 (IL-2) is a potent cytokine that regulates immune responses and has shown promising therapeutic efficacy in various diseases. The development of IL-2 human recombinant using yeast expression systems has provided a valuable biopharmaceutical tool for immunotherapy. This research paper explores the production process, characteristics, and therapeutic applications of IL-2 human recombinant derived from yeast, highlighting its potential as an immunotherapeutic agent.
IL-2 is a critical cytokine involved in the regulation of immune responses, including the activation and proliferation of T cells and natural killer (NK) cells. The use of IL-2 as a therapeutic agent has been limited by challenges associated with production and stability. However, the development of IL-2 human recombinant using yeast expression systems has overcome these limitations, making it an attractive biopharmaceutical for immunotherapy.
Production Process and Characteristics:
IL-2 human recombinant derived from yeast is produced through recombinant DNA technology, utilizing yeast cells as expression hosts. Yeast expression systems offer advantages such as high expression levels, cost-effectiveness, and post-translational modifications that resemble those in human cells. The resulting IL-2 human recombinant possesses similar biological activity to native IL-2, with the ability to bind to IL-2 receptors and stimulate immune cell proliferation and activation.
IL-2 human recombinant derived from yeast has shown promise in the treatment of several diseases. It has been investigated as an immunotherapeutic agent for cancer, particularly in combination with other treatment modalities such as immune checkpoint inhibitors. IL-2 human recombinant has also demonstrated potential in the treatment of autoimmune disorders, including rheumatoid arthritis and psoriasis. Furthermore, it has been explored in the context of infectious diseases and as an adjuvant in vaccines.
Advantages and Challenges:
The use of yeast expression systems for producing IL-2 human recombinant offers several advantages, including scalability, cost-effectiveness, and the ability to generate post-translational modifications that enhance biological activity. However, challenges remain, such as optimizing expression yields, purification processes, and ensuring product consistency and stability. Further research is needed to address these challenges and improve the overall feasibility and clinical efficacy of IL-2 human recombinant derived from yeast.
IL-2 human recombinant derived from yeast represents a promising biopharmaceutical tool for immunotherapy. Its production using yeast expression systems offers advantages in terms of scalability, cost-effectiveness, and biological activity. The therapeutic applications of IL-2 human recombinant extend to various diseases, including cancer and autoimmune disorders. Continued research and development efforts are crucial to optimizing production processes, addressing challenges, and unlocking the full potential of IL-2 human recombinant as an immunotherapeutic agent.
- Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180-190.
- Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.
- Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595-601.
- Charych DH, Hoch U, Langowski JL, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22(3):680-690.
- Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228(3):307-319.